Recruiting studies: Hepatocellular Carcinoma Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta
Phase 1/Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT06811116 Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03949231 Phase II Trial of Immunonutrition in Hepatectomy
NA · 1 location(s) · Tata Memorial Centre · NCT07395635 Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Mary Feng, MD · NCT04430452 Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
Phase 3 · 1 location(s) · Linhui Peng · NCT07267806 Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With
Phase 3 · 3 location(s) · Beijing Shenogen Biomedical Co., Ltd · NCT05594927 Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metast
Phase 2 · 16 location(s) · Academic and Community Cancer Research United · NCT05168163 Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06172205 Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Phase 2/Phase 3 · 11 location(s) · UNICANCER · NCT06904170 A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval
Phase 1 · 19 location(s) · AstraZeneca · NCT07391670 A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Phase 3 · 1 location(s) · Akeso · NCT05489289 A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Ca
Phase 2/Phase 3 · 2 location(s) · Zhejiang Raygene Pharmaceuticals Co., Ltd · NCT06844357 Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer
NA · 1 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT04745390 Adjuvant TACE in HCC With High-risk Recurrence Factors
Phase 3 · 1 location(s) · Guangxi Medical University · NCT07417397 A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With
Phase 3 · 4 location(s) · Akeso · NCT06371157 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285 Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition Af
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT03942328 Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04380545 The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT03368651 Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-
Phase 3 · 139 location(s) · NRG Oncology · NCT07166406 AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448 Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07186621 TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NA · 1 location(s) · Third Affiliated Hospital, Sun Yat-Sen University · NCT05984511 Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642 Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Phase 2 · 4 location(s) · Emory University · NCT07174570 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381 Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Phase 2/Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03755739 the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
Phase 2/Phase 3 · 5 location(s) · Shandong New Time Pharmaceutical Co., LTD · NCT05408221 Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
Phase 3 · 1 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT03895359

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.